Evidence to suggest that CSCs have an impact on survival, possibly through platinum-resistance mechanisms, includes data that the five-year survival rate of CD133+ patients was significantly lower than that of CD133−patients; furthermore, the expression of CD133 is reportedly an independent prognostic factor in some studies, thus providing the first evidence of the importance of CSC markers as potential diagnostic and prognostic indicators in lung cancer patients [34]. The gene discussed is PROM1; the disease is lung carcinoma.